Publications & Presentations in the therapeutic area :

Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.

Jensen J.T., Reinecke I., Post T.M. , Lukkari-Lax E. , Hofmann B.M, Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs. Contraception, 2023. [Link to publication].

An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes

Reinecke I., Hofmann B., Mesic E., Drenth H.J., Garmann D. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol: 1639-1654, 2018. [Link to publication] 

Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data

Bosch R., Gao W., Vargo R., Baliathan C., Fancourt C., Kothare P.A., Kjellson M.C., Karlsson M. and Post T., Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data to translate Glucose Insulin dynamics between Healthy Humans and Non-Human Primates. PAGE.(2015) [Link to publication]

Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis

Berkhout J., Stone J.A., Verhamme K.M., Stricker B.H., Sturkenboom M.C., Danhof M. and Post T.M., Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis, CPT Pharmacometrics Syst Pharmacol., 4(9): 516-526. doi: 510.1002/psp1004.12006. Epub 12015 Aug 12022., 2015. [Link to publication]

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone

Reif S., Snelder N. and Blode H., Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study, J Fam Plann Reprod Health Care., 39(2): e1. doi: 10.1136/jfprhc-2012-100397., 2013. [Link to publication]

Mechanism-based model of effect of co-administration of exogenous testosterone and progestogens on the hypogonadalaxis in men

Strougo A., Elassais-Schaap J., Greef R.d. and Drenth H., Mechanism-based model of effect of co-administration of exogenous testosterone and progestogens on the hypogonadalaxis in men. PAGE. (2007). [Link to publication]